Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study

Key Points

Treatment response correlates with pre-treatment T cells and DLL3 expression levels, indicating potential biomarkers.
The scatter plot illustrates the relationship, shedding light on how treatment response varies in individuals.
Phase 1b trial demonstrates early findings on the safety and efficacy of tarlatamab in targeted patient populations.
These observations highlight the need for further exploration into T cell activity and DLL3 levels as treatment indicators.

Answers are grounded in this paper and cite their sources.

Phase 1b trial reports treatment response linked to pre-treatment T cells and DLL3 expression in neuroendocrine prostate cancer.

Supplementary Figure S3. Scatter plot for treatment response as a relationship between pretreatment T cells and DLL3 expression.

No takes yet. Share an insight, caveat, or question.

Aggarwal et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share